Skip to content
SHM Abstracts | Society of Hospital Medicine Logo
  • Home
  • Meetings Archive
  • Browse By Category
  • Browse By Keyword
  • Search
  • Home
  • Meetings Archive
  • Browse By Category
  • Browse By Keyword
  • Search
Search2020-05-20T12:01:36-05:00
Search
Search by Abstract Number, Title, Keyword, or Authors
Category
Sub-Category

(Optional)

Session Type
Meeting
Search Results for Opioid
Plenary Presentations
Abstract Number: 0003
A HOSPITALIST-LED TEAM INCREASES INITIATION OF MEDICATIONS FOR OPIOID USE DISORDER TREAMTENT
SHM Converge 2025
Background: Hospitalizations related to opioid use disorder (OUD) are rising, creating opportunities to initiate medications for opioid use disorder (MOUD) and connect patients with outpatient resources.1,2 Despite evidence that MOUD reduces morbidity and mortality, most patients fail to receive evidence-based treatment during hospitalization.3-6 Addiction consultation services are becoming the standard of care to address this [...]
Oral Presentations
THE B-TEAM (BUPRENORPHINE): MEDICATION-ASSISTED TREATMENT FOR PATIENTS WITH OPIOID USE DISORDER IN THE HOSPITAL
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Despite a public health crisis – over 500,000 individuals have died from opioid overdoses since 2000 – and the availability of effective therapies, most patients with Opioid Use Disorder (OUD) are not offered treatment. Medication-Assisted Treatment (MAT), such as with buprenorphine, is associated with significantly higher rates of abstinence and follow-up, lower rates of [...]
Oral Presentations
Abstract Number: 13
INPATIENT INTEGRATIVE MEDICINE – A CONSULT SERVICE FOR FUNCTIONAL DISEASES
SHM Converge 2024
Background: Despite medical advancements for organic and structural diseases, effectively managing acute and chronic functional pain syndromes remains a daunting challenge for hospitalists. Standard inpatient treatments frequently fail to adequately control symptoms, often compelling hospitalists to shift from diagnostics to the contentious task of tapering opioids in patients with legitimate pain. This pivot can lead [...]
Oral Presentations
Abstract Number: Oral
A BUPRENORPHINE PROGRAM FOR HOSPITALIZED PATIENTS WITH OPIOID USE DISORDER INCREASES INPATIENT TREATMENT AND OUTPATIENT FOLLOW-UP IN ADDICTION TREATMENT
SHM Converge 2021
Background: Despite evidence that the use of medications for patients with opioid use disorder (OUD) leads to reduced mortality and improved engagement in outpatient addiction treatment, these life-saving medications are underutilized in the hospital setting. This study reports the outcomes of a hospitalist-led interprofessional and multidisciplinary inpatient program, known as the B-Team (buprenorphine team), to [...]
Oral Presentations
Abstract Number: Oral
DECREASING RISK OF OPIOID OVERDOSES IN HOSPITALIZED PATIENTS
Hospital Medicine 2020, Virtual Competition
Background: There were approximately 46,000 opioid overdose deaths in 2017. It is known that opioid overdose risk is increased in patients with a diagnosis of substance use disorder, prior opioid overdose, and high suspicion of risk as assessed by clinical teams. The Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression (RIOSORD) is a validated [...]
Oral Presentations
Abstract Number: Oral
RACIAL AND ETHNIC DISPARITIES IN OPIOID PRESCRIBING ON HOSPITAL DISCHARGE FROM AN INTERNAL MEDICINE SERVICE
Hospital Medicine 2020, Virtual Competition
Background: Prior studies have found racial disparities in how patients are assessed for pain and prescribed opioids from emergency department and surgical settings. However, we do not know whether similar disparities exist among general medicine inpatients. We examined opioid prescriptions at discharge among adults admitted to the general medicine service at our medical center, with [...]
Oral Presentations
THE B-TEAM (BUPRENORPHINE): MEDICATION-ASSISTED TREATMENT FOR PATIENTS WITH OPIOID USE DISORDER IN THE HOSPITAL
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Despite a public health crisis – over 500,000 individuals have died from opioid overdoses since 2000 – and the availability of effective therapies, most patients with Opioid Use Disorder (OUD) are not offered treatment. Medication-Assisted Treatment (MAT), such as with buprenorphine, is associated with significantly higher rates of abstinence and follow-up, lower rates of [...]
Oral Presentations
Abstract Number: 13
INPATIENT INTEGRATIVE MEDICINE – A CONSULT SERVICE FOR FUNCTIONAL DISEASES
SHM Converge 2024
Background: Despite medical advancements for organic and structural diseases, effectively managing acute and chronic functional pain syndromes remains a daunting challenge for hospitalists. Standard inpatient treatments frequently fail to adequately control symptoms, often compelling hospitalists to shift from diagnostics to the contentious task of tapering opioids in patients with legitimate pain. This pivot can lead [...]
Abstract Number: 35
FIT FOR A KIT: A HOSPITAL-BASED, STUDENT-LED HARM REDUCTION GROUP
SHM Converge 2023
Background: The American opioid epidemic is a public health emergency, with over 100,000 opioid-related overdose deaths occurring in 2021 (1). Harm reduction treatment models, formulated with the goal of reducing the negative consequences of opioid use, have been implemented as an alternative approach in minimizing opioid overdose and mortality (2). With approximately 4-11% of hospitalized [...]
Abstract Number: 59
SUBCUTANEOUS METHYLNALTREXONE IN PATIENTS WITH ADVANCED ILLNESS AND OPIOID-INDUCED CONSTIPATION AND THE IMPACT OF BASELINE OSMOTIC AND STIMULANT LAXATIVE USE
SHM Converge 2021
Background: Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC), which can be a serious consequence of opioid analgesia. We evaluated whether baseline osmotic agent (eg, milk of magnesia, polyethylene glycol, lactulose, sorbitol) or stimulant (eg, senna, bisacodyl) use affects the efficacy and safety of MNTX among a subgroup of [...]
1 2 3 … 9 Next ›
  • This Week

  • This Month

  • All Time

  • This Week

  • FEEDBACK THAT WORKS: IMPROVED BILLING THROUGH AUTOMATED PEER COMPARISON

  • A CASE OF AMANTADINE INDUCED LIVEDO RETICULARIS IN A PATIENT WITH MULTIPLE SCLEROSIS

  • NALTREXONE – INDUCED KRATOM WITHDRAWAL: A CALL FOR AWARENESS

  • LOSARTAN-INDUCED ELECTROLYTE DEPLETION

  • Cannabis Withdrawal Induced Hypertensive Urgency

  • This Month

  • FEEDBACK THAT WORKS: IMPROVED BILLING THROUGH AUTOMATED PEER COMPARISON

  • NALTREXONE – INDUCED KRATOM WITHDRAWAL: A CALL FOR AWARENESS

  • A CASE OF AMANTADINE INDUCED LIVEDO RETICULARIS IN A PATIENT WITH MULTIPLE SCLEROSIS

  • LOSARTAN-INDUCED ELECTROLYTE DEPLETION

  • Cannabis Withdrawal Induced Hypertensive Urgency

  • All Time

  • FEEDBACK THAT WORKS: IMPROVED BILLING THROUGH AUTOMATED PEER COMPARISON

  • ADDERALL INDUCED ISCHEMIC COLITIS

  • A CASE OF SKIN NECROSIS CAUSED BY INTRAVENOUS XYLAZINE ABUSE

  • Bc Powder Causing Intracerebral Bleed: Pitfalls of Overlooking Dosage of Seemingly Innocuous Otc Formulations

  • RECOGNIZING S1Q3T3 FOR WHAT IT IS: A NONSPECIFIC PATTERN OF RIGHT HEART STRAIN

© Society of Hospital Medicine | All Rights Reserved | Privacy Policy
Page load link
Go to Top